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A b s t r a c t
Introduction: Currently, Cardiology Centres are overfilled with patients with degenerative aortic valve stenosis (DAS), usually 
eldery, with severe concommittant comorbidities, who are referred for further decisions and possible intervention. 
Aim: To evaluate changes in the risk profile of patients with severe DAS admitted to the cardiology department a decade ago 
compared with patients currently being admitted. 
Material and methods: We retrospectively evaluated all patients admitted with confirmed severe DAS, hospitalized during 
2005–2006 (group I: 140 patients) and in 2016 (group II: 152 patients), admitted for aortic valve intervention. A standard transtho-
racic echocardiogram, cardiovascular symptom and risk factor distribution, perioperative risk with the logistic EuroSCORE II and STS 
mortality scores were obtained.
Results: Patients in group II were significantly older (p < 0.001), had more cardiovascular risk factors, and more often presented 
with atrial fibrillation (27% vs. 11.4%, p = 0.001), renal impairment (34.9% vs. 22.8%; p = 0.024), severe lung disease (17.1% vs. 
2.1%, p < 0.001), and extracardiac arteriopathy (40.1% vs. 17.8%, p < 0.001). The aortic valve area (AVA) (p = 0.356), mean-trans-
valvular pressure gradient (p = 0.215), and left ventricular ejection fraction (p = 0.768) were similar in both groups. However, the 
prevalence of pulmonary hypertension, severe mitral regurgitation, and low-flow, low-gradient DAS were 3.1-, 8.4- and 1.84-fold 
more frequent in group II than group I. The percentages of subjects with EuroSCORE II and STS scores ≥ 4% in 2005–2006 were 7.1% 
and 6.4%, as compared to 27% and 26.3% in 2016 (both p < 0.001). 22% of patients in 2016, as compared to 31% in 2005/2006, 
were considered ineligible for DAS intervention.
Conclusions: In just a decade, the risk profile of patients admitted with DAS has increased hugely, mainly due to older age, 
accumulation of comorbidities and more advanced disease at presentation. Although transcatheter aortic valve intervention has 
expanded the indications for intervention in high-risk patients, the number of patients disqualified from interventional treatment 
remains high.
Key words: degenerative aortic valve stenosis, transcatheter aortic valve intervention, aortic valve replacement, risk assess-
ment, EuroSCORE II, STS score.
S u m m a r y
Currently, Cardiology Centers are overfilled with patients with degenerative aortic valve stenosis, who are referred for fur-
ther decisions and possible intervention. In this study we evaluated differences in clinical performance, associated comorbid-
ities, echocardiographic findings, and the surgical mortality scores in patients referred to intervention currently and 10 years 
ago. Also, we compared the proportion of patients reffered to invasive treatment and considered ineligible in years 2005–2006 
vs. in 2016.
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Introduction 
Degenerative aortic valve stenosis (DAS) most com-
monly affects elderly patients [1, 2] and its prevalence is 
estimated to be 2–7% in people over the age of 65 [3, 4]. 
As a result of global population aging, a rapid increase in 
the incidence of DAS is noted [5, 6]. 
Aortic valve degeneration is characterized by sys-
tematic valve calcification and narrowing, and several 
risk factors of stenosis progression have been proposed 
[3–10]. Rapid DAS progression may be associated with 
the extent of aortic valve and muscle calcifications, the 
disease activity assessed with positron emission tomog-
raphy, or CT calcium scoring, or high inflammatory status 
(CRP, RANTES), also in patients with diabetes, concomi-
tant coronary artery disease, or hemodialysis [7–9]. How-
ever, the progression is individually variable and cannot 
be easily predicted [7–10]. 
In the beginning, it is typically associated with a peak 
and mean transvalvular pressure gradient increase, left 
ventricular hypertrophy, and left atrial enlargement. 
Along with further DAS deterioration, other cardiac dis-
orders such as left ventricular dysfunction, mitral valve 
insufficiency, atrial arrhythmias, pulmonary hyperten-
sion, and right ventricular dysfunction worsen a patient’s 
prognosis [10]. Therapeutic decision-making in the el-
derly with advanced, complicated DAS, accompanied by 
other cardiac and extracardiac problems, is difficult. At 
the time of patient referral for invasive intervention, the 
procedure-related 30-day mortality risk, using the Euro-
SCORE II and Society of Thoracic Surgeon risk score (STS), 
is frequently unacceptably high [11–14]. 
Echocardiography plays the principal role, not only in 
DAS diagnosis, but more importantly, is crucial in cardiac 
risk monitoring of congestive heart failure and sudden 
cardiac death [10, 15, 16]. The complementary role of bio-
markers in the process of evaluation of DAS still requires 
further investigation [17]. If complicated DAS occurs, it is 
associated with a rapidly increasing risk of heart failure 
and death in patients managed conservatively, as well as 
difficult decisions on further management due to periop-
erative mortality and morbidity risk. 
As per current guidelines, intervention for DAS is rec-
ommended in patients with symptomatic severe DAS 
(level of evidence: IB) and in patients with moderate DAS 
referred for coronary artery bypass or ascending aorta 
surgery (level of evidence: IIa-C) [11]. Furthermore, AVR 
is recommended in asymptomatic patients with severe 
DAS and unexplained left ventricular dysfunction (LVEF 
< 50%) (level of evidence: IC), as well as an abnormal 
result of the exercise test (level of evidence: IC).
Aim
The main objective of the present study was to com-
pare the risk profile and comorbidities affecting perioper-
ative risk in patients with symptomatic moderate-to-se-
vere DAS referred for aortic stenosis treatment in 
2005–2006, as compared to patients admitted in 2016.
Material and methods
The study group consisted of 292 patients with con-
firmed symptomatic severe DAS (defined as an aortic 
valve area < 1.0 cm2 from the continuity equation) referred 
to our department for aortic valve stenosis intervention.
Group I consisted of 140 consecutive patients (87 men, 
53 women), mean age: 64.1 ±8.9 years (range: 40–83), 
admitted to the hospital between January 2005 and De-
cember 2006. 
Group II comprised 152 consecutive patients (75 men, 
77 women), mean age: 73.1 ±9.6 years (range: 47–91), 
admitted to the hospital between January 2016 and De-
cember 2016.
All subjects were evaluated, including an assessment 
of clinical symptoms with the New York Heart Associa-
tion (NYHA) Classification and the Canadian Cardiovas-
cular Society Grading System for exertion-induced an-
gina (CCS), and the distribution of major cardiovascular 
risk factors (gender, age, hypertension, diabetes mellitus 
type II, hyperlipidemia). 
Transthoracic echocardiography, carotid ultrasonog-
raphy, and coronary angiography were performed.
Perioperative risk was assessed with the EuroSCORE II 
and STS scores.
The study protocol was consistent with the require-
ments of the Helsinki Declaration, and approved by the 
local Institutional Ethics Committee. All subjects gave in-
formed consent for participation in the study.
Coronary angiography was performed in all patients 
using COROSCOP (Siemens), equipped with Quantcor 
QCA V 2.0 quantitative coronary analysis software. Pa-
tients with at least one lesion ≥ 50% reduction in lumen 
diameter within the main branches of the coronary arter-
ies were considered to have significant CAD.
Echocardiographic study
All patients underwent a complete echocardiographic 
study in compliance with the guidelines of the Europe-
an Association of Cardiovascular Imaging [16]. The peak 
and mean gradient through the aortic valve, the aortic 
valve area (AVA), left ventricular ejection fraction (LVEF), 
grading of mitral valve insufficiency, right ventricular dys-
function, and pulmonary hypertension (PH) grading were 
calculated in groups I and II. 
Carotid artery ultrasonography
High-resolution B-Mode, color Doppler, and pulse 
Doppler ultrasound of both carotid arteries were per-
formed with an ultrasound machine (TOSHIBA APLIO) 
featuring a linear-array 5–10 MHz transducer. The degree 
of carotid stenosis was assessed through an increase in 
the peak systolic and end-diastolic velocities (according 
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to the Bluth criteria) [18]. The carotid artery stenosis was 
considered significant (> 50% lumen reduction) if peak 
systolic velocity was > 1.3 m/s, end-diastolic velocity 
> 0.4 m/s, and lumen reduction exceeded 70% on trans-
verse scans. Experienced sonographers who had no pri-
or knowledge of the subject’s clinical and angiographic 
characteristics obtained all scans. The importance of ca-
rotid artery ultrasonography in DAS has been previously 
demonstrated [19, 20].
Perioperative risk calculators: EuroSCORE II 
and STS score 
STS score – the Society of Thoracic Surgeons-Pre-
dicted Risk of Mortality score (STS-PROM) and the Eu-
ropean System for Cardiac Operative Risk Evaluation 
(EuroSCORE) model (additive and logistic) were used to 
evaluate the risk in all patients [12, 13].
Two experienced cardiologists working together as-
sessed perioperative risk using calculators which are 
freely available online: STS score (http://riskcalc.sts.org/
stswebriskcalc/#/calculate) and EuroSCORE II (http://
www.euroscore.org/calc.html). Variables included in both 
scores were judged according to guidelines supplied to 
databases. 
Analyzed variables included in the calculation of 
scores were defined as follows:
Data on disabling ischemic stroke were obtained from 
a stroke unit and sourced from available medical documen-
tation. Brain imaging was obtained either with computed 
tomography (CT) or magnetic resonance imaging (MRI).
Data on chronic lung disease were collected from 
available medical documentation and from results of 
pulmonary function tests. 
Estimated glomerular filtration rate (eGFR) was calcu-
lated using the MDRD formula and for the EuroSCORE II 
calculator using the Cockcroft-Gault formula. A history of 
peripheral artery disease including claudication (upper 
and lower extremities, renal, mesenteric, and abdominal 
aortic systems) was collected from the patient’s medical 
history. Data on previous cardiac interventions, procedure 
urgency, critical perioperative state, and concomitant car-
diac surgery were obtained from medical documentation.
Statistical analysis
Continuous variables are presented as mean ± SD, 
categorical variables are expressed as frequencies and 
percentages. Means of analyzed parameters across 
groups were tested with the analysis of variance (ANOVA) 
test and frequencies were compared using the c2 test for 
independence.
The normal distribution of studied variables was 
determined using the Shapiro-Wilk test. Differences be-
tween mean values of echocardiographic parameters 
were verified using the Mann-Whitney U test as the dis-
tribution of variables was found not to be normal. The 
U  test results were presented as the median and inter-
quartile range.
Statistical analyses were performed using Statistica 
12.0 software. Statistical significance was assumed at 
p < 0.05.
Results 
Basic characteristics of patients
Baseline characteristics of study participants are 
shown in Table I. Subjects in group II, when compared 
with those in group I, were significantly older. In com-
parison to group I, group II patients were more often fe-
males and showed a significantly increased prevalence 
of classic cardiovascular risk factors such as hyperten-
sion, diabetes mellitus, and hyperlipidemia (Table I). 
Group I patients, when compared to group II patients, 
presented more frequently with symptoms assessed as 
grade 2 to 4 according to the NYHA classification, but 
reported fewer symptoms according to the CCS scale 
(Table I). However, there was no significant difference 
with respect to prevalence of symptoms in class 4, both 
according to the NYHA as well as the CCS classification 
(Table I).
Echocardiography results
A comparison of echocardiographic characteristics is 
displayed in Table II. On echocardiography, there were no 
significant differences between groups with respect to 
LVEF (57.5 ±12.1%, median 60% vs. 55 ±12.1%, median 
60%, p = 0.768), mean aortic valve gradients (48.6 ±19.9 
vs. 46.2 ±15.6 mm Hg, p = 0.215), and the AVA (0.87 ±0.3 
vs. 0.90 ±0.32 cm2, p = 0.356) (Table II). Peak aortic gra-
dient was higher in group I vs. group II (82.3 ±27.7 vs. 76 
±25.5 mm Hg, p = 0.05). 
Low-flow-low-gradient DAS was more frequent in 
group II vs. group I subjects (11.8% vs. 6.4%, p = 0.037). 
PH was more frequent in group II vs. group I  subjects 
(27% vs. 8.6%, p < 0.001). Severe mitral regurgitation 
was more frequent in group II vs. group I subjects (5.9% 
vs. 0.7%, p = 0.015).
Perioperative risk factor distribution  
and comorbidities included in STS score  
and EuroSCORE II
Risk factors and comorbidities influencing periopera-
tive risk scores are shown in Table III. 
In group II vs. group I, female subjects were more 
frequent (50.7% vs. 37.9%, p = 0.028). Extracardiac ar-
teriopathy (40.1% vs. 17.8%, p < 0.001), renal dysfunc-
tion (34.9% vs. 22.8%, p = 0.024), atrial fibrillation (27% 
vs. 11.4%, p = 0.001), and severe chronic lung disease 
(17.1% vs. 2.1%, p < 0.001) were all more prevalent in 
group II vs. group I patients. The prevalence of coronary 
artery disease (at least one major coronary artery with 
lumen reduction exceeding 50%) was similar in both 
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groups (42.1% vs. 46.7%, p = 0.433), while rates of pre-
vious myocardial infarction (16.4% vs. 8.6%, p = 0.043) 
and PCI (25.6% vs. 9.2%, p < 0.01) were more frequent in 
group II vs. group I subjects. 
Perioperative risk scores
The mean perioperative mortality risk scores in group II 
were significantly higher than those in group I  (Euro-
SCORE II: 3.52 ±3.97% vs. 1.26 ±2.8% p < 0.001; STS 
mortality score: 3.14 ±2.7% vs. 1.12 ±2.43; p < 0.001) 
(Figure 1 A).
The prevalence of subjects with high perioperative 
mortality risk ≥ 4% was significantly higher in group II 
than group I. This was with respect to the EuroSCORE II: 
41 (27%) vs. 10 (7.1%) (p < 0.001) and STS: 40 (26.3%) 
vs. 9 (6.4%) (p < 0.001) (Figure 1 B).
Treatment options
In the year 2005/2006, 69% of patients were referred 
for AVR, while 31% of subjects were given optimal med-
ical treatment (OMT) without intervention on DAS, due 
to unacceptably high-operative risk. In the year 2016, 
although the risk profile of patients increased, 53% of 
patients were referred for AVR, 22% for TAVI and 3% for 
balloon aortic valvuloplasty (BAV). Still, 22% of subjects 
were considered ineligible for DAS intervention and they 
were referred for OMT (Figure 2).
Discussion
The most important finding from our study is that in 
a period of just one decade, patients with DAS are cur-
rently referred for intervention at a more advanced stage 
of DAS. Whereas echocardiographic parameters of the 
AVA, mean-transvalvular pressure, and LVEF were simi-
lar in both groups, the prevalence of moderate-to-severe 
PH, severe mitral insufficiency, or AF increased 3.1-, 8-, 
and 2.5-fold in patients evaluated recently for DAS. Both 
PH and AF independently increase perioperative risk and, 
additionally, PH has a negative impact on long-term out-
come [21]. Furthermore, low-flow, low-gradient DAS was 
Table I. Baseline characteristics of study participants
Parameter DAS patients 2005/2006 (n = 140) DAS patients 2016 (n = 152) P-value
Demographic data:
Age, mean ± SD*# [years] 64.1 ±8.9 73.1 ±9.6 < 0.001
Median (Q1 : Q3) 65 (57 : 71) 74 (67 : 81)
  Female, n (%)*# 53 (37.9) 77 (50.7) 0.028
Clinical symptoms, n (%):
NYHA ≥ II*# 135 (96.4) 129 (84.9) 0.001
NYHA = IV*# 4 (2.9) 4 (2.6) 0.906
CCS ≥ II* 36 (25.7) 58 (41.4) 0.023
CCS = IV*# 1 (0.7) 3 (2.0) 0.355
Risk factors, n (%):
Hypertension* 96 (68.6) 148 (97.3) < 0.001
Diabetes* 25 (17.8) 54 (35.5) 0.001
On insulin*# 3 (2.1) 15 (9.9) 0.006
Dyslipidemia 111 (79.3) 150 (98.6) < 0.001
CAD*# 59 (42.1) 71 (46.7) 0.433
Previous MI*# 12 (8.6) 25 (16.4) 0.043
Previous PCI* 6 (9.2) 39 (25.6) < 0.01
Laboratory results, mean ± SD:
LDL cholesterol [mmol/l] 3.4 ±1.00 2.7 ±1.00 < 0.001
Creatinine [µmol/l] 87.7 ±21.2 88.4 ±23.4 0.801
Hemoglobin [g/dl] 13.7 ±1.6 13.1 ±1.6 0.435
*Parameters included in STS score, #parameters included in EuroSCORE II.
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observed twice as often in 2016 as compared to 2005–
2006. Therefore, patients with newly recognized DAS 
should undergo careful assessment using serial echocar-
diographic and stress tests. This would aid in optimally 
timing required interventions.
Thus, echocardiographic findings are valuable, being 
able to indicate high transvalvular gradient, massive and 
extensive calcifications, rapid disease progression, as 
well as atrium enlargement and right ventricular dys-
function [22]. Notably, the risk of intervention signifi-
cantly increases with DAS progression. Furthermore, in 
asymptomatic or scarcely symptomatic patients, stress 
testing should be used to identify high-risk features 
including reduced exercise tolerance, exercise-induced 
symptoms, and absolute or relative hypotension [23].
In the present study, symptoms according to NYHA 
classification in classes 2 and higher were observed in 
96.4% of the group I population and in 85% of patients 
with DAS in 2016. There is substantial controversy over 
the optimal timing of intervention for these patients, as 
some advocate early intervention while others favor con-
servative management until symptom onset [24].
On the one hand, sudden death risk in truly clini-
cally asymptomatic patients with severe DAS was esti-
mated at 1–1.5% per year [25], while intervention risk 
may exceed 3% [11]. Thus, some experts would advo-
cate a  ‘watchful waiting’ attitude. However, we have 
demonstrated that the policy of ‘watchful waiting’ until 
symptoms (arrhythmias, pulmonary hypertension or con-
gestive heart failure) appear in higher classes should be 
reconsidered carefully, as this leads to high perioperative 
mortality scores in patients. In our study, at the point of 
invasive DAS management, EuroSCORE II and STS scores 
of 4% or higher were present in 26–27% of patients, as 
compared to 6–7% in 2005–2006. 
This is in line with other observational studies in-
dicating that the ‘watchful waiting’ attitude leads to 
advanced patient age and the increasing number of 
Table II. Echocardiographic findings in study participants





Left ventricle ejection fraction, mean ± SD (%)*#: 57.5 ±12.1 55 ±12.1 0.768
Median (Q1 : Q3) 60 (51 : 65) 60 (50 : 65)
LVEF < 50%, n (%) 26 (18.6) 28 (18.4) 0.974
Mean aortic gradient, mean ± SD [mm Hg]: 48.6 ±19.9 46.2 ±15.6 0.215
Median (Q1 : Q3) 48 (35 : 61) 46 (37 : 54)
Number of patients with MG > 40 mm Hg, n (%) 97 (69.3) 95 (62.5) 0.222
Aortic valve area, mean ± SD [cm2] 0.87 ±0.3 0.9 ±0.32 0.356
Low-flow low-gradient DAS, n (%) 7 (6.4) 18 (11.8) 0.037
Pulmonary hypertension, n (%)#:
Moderate (RVSP: 31–55 mm Hg) 8 (5.7) 33 (21.7) < 0.001
Severe (RVSP > 55 mm Hg) 4 (2.9) 8 (5.3) 0.300
Overall (RVSP ≥ 31 mm Hg) 12 (8.6) 42 (27) < 0.001
 Concomitant aortic valve insufficiency, n (%)*:
Moderate 12 (8.6) 20 (13.1) 0.210
Severe 6 (4.2) 1 (0.6) 0.043
Overall 18 (12.8) 21 (13.7) 0.801
Concomitant severe mitral valve stenosis, n (%)* 3 (2.1) 2 (1.3) 0.586
Concomitant mitral valve regurgitation, n (%)*:
Moderate 14 (10) 16 (10.5) 0.970
Severe 1 (0.7) 9 (5.9) 0.015
Overall 15 (10.7) 25 (16.4) 0.155
Ascending aorta diameter > 45 mm, n (%)# 5 (3.5) 6 (3.9) 0.866
*Parameters included in STS score, #parameters included in EuroSCORE II.
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concomitant comorbidities which increase STS and Euro-
SCORE II risk [12, 13].
Furthermore, Genereux et al. found in a meta-analysis 
of 4 retrospective studies that patients with severe asymp-
tomatic DAS have a 3.5-fold higher rate of all-cause death 
when managed with a conservative strategy compared to 
AVR [22]. Moreover, this meta-analysis favors intervention 
over optimal medical treatment in terms of cardiovascular 
risk reduction, e.g. sudden cardiac death [22]. 
We observed in our present study that currently, as 
compared to 2005/2006, there are fewer patients with 
DAS and symptoms of congestive heart failure; however, 
these patients have higher scores using the EuroSCORE II 
and STS calculators. This is due to a significant increase 
in the prevalence of associated cardiovascular risk fac-
tors and vital comorbidities such as lung disease, pe-
ripheral artery occlusive disease, and disabling stroke in 
recently admitted patients with DAS. The results from our 
Figure 1. A – Comparison of mean EuroSCORE II and STS scores in group I and group II, B – prevalence of pa-
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p < 0.001 p < 0.001p < 0.001 p < 0.001
Table III. Comorbidities included in STS score and EuroSCORE II 





Severe chronic lung disease, n (%)*# 3 (2.1) 26 (17.1) < 0.001
Renal dysfunction (eGFR < 60), n (%)*# 32 (22.8) 53 (34.9) 0.024
Extracardiac arteriopathy (carotid or PAD), n (%)*# 25 (17.8) 61 (40.1) < 0.001
Atrial fibrillation, n (%)* 16 (11.4) 41 (27) 0.001
Previous ischemic stroke/TIA, n (%)* 8 (5.7) 17 (11.2) 0.095
Significant coronary artery disease (> 50%), n (%)* 59 (42.1) 71 (46.7) 0.433
Previous MI, n (%)*#: 12 (8.6) 25 (16.4) 0.043
< 21 days before intervention 0 (0) 0 (0) N/A
≤ 90 days before intervention 0 (0) 6 (3.95) 0.049
Previous PCI, n (%)* 6 (9.2) 39 (25.6) < 0.001
Previous cardiac surgery, n (%)*# 5 (3.7) 8 (5.3) 0.484
Intervention urgency, n (%):
Elective*# 137 (98) 141 (92.76) 0.042
Urgent*# 1 (0.7) 9 (5.92) 0.015
Emergency*# 2 (1.4) 2 (1.32) 0.933
Shock/Critical preoperative status, n (%)*# 1 (0.7) 4 (2.63) 0.207
Active endocarditis, n (%)*# 0 (0) 0 (0) N/A
Immunocompromised, n (%)* 1 (0.7) 6 (3.95) 0.071
Poor mobility, n (%)# 8 (5.7) 13 (8.6) 0.348
*Parameters included in STS score, #parameters included in EuroSCORE II.
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Figure 2. A  – Patients referred for aortic valve replacement (AVR) or optimal medical treatment (OMT) in 
2005–2006. B – Patients referred for AVR, OMT, transcatheter aortic valve replacement (TAVI) and balloon aortic 
valvuloplasty (BAV) in 2016






study are in line with recent epidemiological data which 
show changes in the profile of patients with valvular 
disease who attend clinics, wards and emergency units 
[6, 8, 26–28]. Hypertension, diabetes, peripheral artery 
disease, renal dysfunction and chronic pulmonary disease 
have a huge influence on perioperative risk [12, 13, 26].
Another problem arises with symptomatic patients 
with DAS referred for intervention. Patient mortality in-
creases dramatically with appearance of symptoms [29], 
exceeding 60% during the 5 years after the time of first 
hospital admission [27]. Cardiac deaths represent more 
than half of cases, with heart failure and sudden death as 
the main causes [30]. In patients over 80 years prognosis 
is even poorer, and the annual mortality reaches up to 
50% [31].
For 15 years, transcatheter aortic valve replacement 
(TAVI) has been a  viable alternative to surgical aortic 
valve replacement (AVR) for high-surgical-risk subjects 
[27]. Data from recent trials suggest that performing 
TAVI in subjects with intermediate periprocedural risk 
(STS below 4%) may be beneficial and have compara-
ble periprocedural mortality results [32]. However, in 
patients with DAS and low-to-intermediate periproce-
dural risk, the primary endpoint of all-cause mortality, 
stroke, or MI was relatively high at 5 years (39.2% among 
TAVI-treated patients and 35.8% in AVR-treated patients, 
p = NS). Notably, the principal concerns regard the high 
rates of pacemaker implantation (about 40% of patients) 
and paravalvular leaks (about 21%) in the TAVI-treated 
patients [33, 34]. Nevertheless, as we face increasing 
periprocedural mortality risk in patients referred for AVR, 
the proportion of patients referred for TAVI will naturally 
increase [35]. Our current study indicates that although 
there is an increase in the risk profile of patients current-
ly admitted, increased access to invasive treatment op-
tions, such as TAVI and AVR, leads to intervention in 78% 
of patients. Still, 22% of subjects in 2016, as compared 
to 30% in 2005-2006, were considered ineligible for DAS 
intervention and were referred for OMT.
Study limitations
The first limitation is that the present study is derived 
from data of one center, based on a population subset 
consisting predominantly of symptomatic patients with 
DAS admitted for intervention. The population of asymp-
tomatic patients with DAS was underrepresented. 
Another study limitation is a  lack of data concern-
ing intervention outcomes, which could present a  real 
perioperative risk comparison between both groups. Be-
cause of this, therapeutic decisions in 2005–2006 cannot 
be directly extrapolated to currently available guidelines 
and therapeutic options. Moreover, TAVI was not avail-
able in 2005–2006 as a standard procedure. Periopera-
tive risk assessment was performed in 2005–2006 using 
the old “logistic” EuroSCORE, which is not compatible 
with the currently used EuroSCORE II. We cannot indi-
cate the proportion of patients in both study periods who 
were a priori disqualified from even referral for the as-
sessment for potential intervention and a priori deemed 
“too high risk” by their GP.
Conclusions
Within one decade, the risk profile of patients ad-
mitted with DAS has significantly increased, which is 
mainly due to the accumulation of comorbidities in ad-
vanced age and more advanced disease at presentation. 
Although new treatment methods such as TAVI have 
expanded the indications for intervention in high-risk 
patients, the number of patients disqualified from inter-
ventional treatment remains high.
A B
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A careful diagnostic and qualification process in pa-
tients with DAS is crucial for obtaining the best results 
and reducing the risk. The referral for intervention of 
DAS should be considered earlier than current recom-
mendations, preferably before echocardiographic fea-
tures of decompensated DAS and symptoms of heart 
failure occur.
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